Cross Country Healthcare, Inc.

DB:XXY Stock Report

Market Cap: €326.8m

Cross Country Healthcare Valuation

Is XXY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XXY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XXY (€9.9) is trading above our estimate of fair value (€9.12)

Significantly Below Fair Value: XXY is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XXY?

Key metric: As XXY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XXY. This is calculated by dividing XXY's market cap by their current revenue.
What is XXY's PS Ratio?
PS Ratio0.2x
SalesUS$1.45b
Market CapUS$340.36m

Price to Sales Ratio vs Peers

How does XXY's PS Ratio compare to its peers?

The above table shows the PS ratio for XXY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
SYAB SYNLAB
1x4.4%€2.5b
V3V VITA 34
0.9x3.1%€72.5m
FME Fresenius Medical Care
0.6x3.8%€12.4b
M12 M1 Kliniken
0.9x8.2%€307.1m
XXY Cross Country Healthcare
0.2x-5.3%€340.4m

Price-To-Sales vs Peers: XXY is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does XXY's PS Ratio compare vs other companies in the DE Healthcare Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.67m
No more companies available in this PS range
XXY 0.2xIndustry Avg. 0.6xNo. of Companies4PS00.40.81.21.62+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: XXY is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is XXY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XXY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: XXY is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XXY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€9.90
€14.69
+48.4%
16.5%€17.89€11.30n/a5
Nov ’25€10.40
€16.83
+61.8%
8.8%€17.57€13.87n/a5
Oct ’25€12.00
€16.83
+40.2%
4.3%€17.19€15.38n/a5
Sep ’25€13.40
€16.83
+25.6%
4.3%€17.19€15.38n/a5
Aug ’25€16.10
€17.30
+7.4%
6.7%€19.46€15.75n/a6
Jul ’25€12.80
€16.91
+32.1%
9.8%€19.54€14.89n/a6
Jun ’25€13.50
€16.91
+25.2%
9.8%€19.54€14.89n/a6
May ’25€16.40
€17.67
+7.8%
14.6%€22.13€14.75n/a6
Apr ’25€17.20
€17.67
+2.7%
14.6%€22.13€14.75n/a6
Mar ’25€16.80
€17.67
+5.2%
14.6%€22.13€14.75n/a6
Feb ’25€19.90
€20.64
+3.7%
8.8%€23.85€18.35n/a6
Jan ’25€20.40
€20.64
+1.2%
8.8%€23.85€18.35n/a6
Dec ’24€18.40
€20.56
+11.7%
9.6%€23.89€17.69n/a6
Nov ’24€21.80
€26.35
+20.9%
13.5%€30.33€20.85€10.405
Oct ’24€23.40
€27.52
+17.6%
20.9%€37.44€20.59€12.005
Sep ’24€22.80
€26.43
+15.9%
20.0%€36.66€20.17€13.406
Aug ’24€23.40
€28.85
+23.3%
18.2%€37.43€23.39€16.106
Jul ’24€25.60
€28.85
+12.7%
18.2%€37.43€23.39€12.806
Jun ’24€23.80
€28.85
+21.2%
18.2%€37.43€23.39€13.506
May ’24€19.80
€34.41
+73.8%
13.7%€40.84€27.68€16.406
Apr ’24€20.20
€34.77
+72.1%
15.1%€42.53€28.35€17.207
Mar ’24€25.00
€35.84
+43.4%
13.7%€42.53€28.83€16.806
Feb ’24€26.20
€37.08
+41.5%
15.4%€42.43€29.23€19.906
Jan ’24€24.40
€37.08
+52.0%
15.4%€42.43€29.23€20.406
Dec ’23€33.80
€38.17
+12.9%
15.4%€43.67€30.09€18.406
Nov ’23€38.40
€36.18
-5.8%
20.3%€45.01€26.01€21.806

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.0%

1Y

-38.8%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.1%

1Y

16.0%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%